Researchers at the European Society of Cardiology conference reported that the drug “Clopidogrel,” the generic name for “Plavix,” a common blood thinner or anticoagulant, should replace aspirin as a daily medication to prevent heart attacks and strokes in people already suffering from at least some degree of heart disease.

Data pooled from about 29,000 patients with coronary artery disease, who participated in seven previous randomized trials, showed that those taking “Clopidogrel” were 14% less likely to face major risks related to heart, vascular, and cerebrovascular diseases compared to those on aspirin, over an average follow-up period of 5.5 years.

These risks include heart attacks, strokes, and death resulting from cardiovascular diseases.

The researchers stated, “These results suggest that Clopidogrel should be considered the optimal choice for preventing platelet aggregation and clot formation in the long term for patients with coronary artery disease.”

They also noted that the study’s findings could influence medical guidelines worldwide and improve patient health outcomes, as “Clopidogrel” is widely available and inexpensive.